The Regulation Places of work of Frank R. Cruz Reminds Buyers of Class Actions on Behalf of Shareholders

0
9
The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, July 28, 2020 (GLOBE NEWSWIRE) – Frank R. Cruz's law firm reminds investors that class action lawsuits have been filed on behalf of the shareholders of the following listed companies. Investors have until the deadlines listed below to file a request from the main plaintiff.

Investors who experience losses on their investments are requested to contact Frank R. Cruz's law firm at 310-914-5007 or by email at fcruz@frankcruzlaw.com to exercise their legal rights in these class actions to discuss.

ProAssurance Corporation (NYSE: PRA)
Class time: April 26, 2019 – May 7, 2020
Main Claimant's Deadline: August 17, 2020

The complaint alleges that ProAssurance provided false and / or misleading information and / or did not disclose throughout the class period: (1) ProAssurance lacked an adequate underwriting process and risk management controls required to maintain adequate loss reserves in its special P& To form C segment; (2) ProAssurance has not properly assessed a large national health account that has suffered losses well above the assumptions made when subscribing to the account; and (3) that ProAssurance was consequently exposed to a significantly increased risk of financial loss and reserves.

Co-Diagnostics, Inc. (NASDAQ: CODX)
Class time: February 25, 2020 – May 15, 2020
Main Claimant's Deadline: August 17, 2020

On February 24, 2020, Co-Diagnostics announced that it had received regulatory approval to sell its COVID-19 tests in the European Community. On April 6, 2020, the company announced that it received emergency approval for its testing from the United States Food and Drug Administration ("FDA"). Finally, on May 14, 2020, after the company continued to confirm its statements about the success of its test in the first quarter results, public reports began that questioned the company's claims of 100% accuracy as the company was reluctant to take tests in the U.S. Later in the day, the U.S. FDA announced publicly that no COVID-19 test was 100% accurate. In the news, the company's share price fell $ 5.06 or more than 22% and closed at $ 17.07 per share on May 15, 2020, injuring investors.

Enphase Energy, Inc. (NASDAQ: ENPH)
Class time: February 26, 2019 – June 17, 2020
Main Claimant's Deadline: August 17, 2020

Shareholders with a loss of $ 150,000 or more are encouraged to contact the company.

The complaint alleges that the defendants provided false and / or misleading information and / or did not disclose throughout the teaching period: (1) that their earnings were excessive both in the United States and internationally; (2) that the Company has used inappropriate accounting practices for deferred income; (3) that the company's reported gross margin widening was overestimated; and that (4) as a result of the foregoing, the defendant's public statements at all relevant times were materially incorrect and misleading.

Chembio Diagnostics, Inc. (NASDAQ: CEMI)
Class time: March 12, 2020 – June 16, 2020
Main Claimant's Deadline: August 17, 2020

In April 2020, the company's COVID-19 antibody test was one of the first to be approved by the United States Food and Drug Administration (FDA) for emergency use ("EUA"). On June 17, 2020, before the market opened, the FDA revoked the EUA for the COVID-19 serology test of Chembio's Dual Path Platform due to concerns about the accuracy of the test. In particular, the FDA found that the “benefits no longer outweigh the risks” and “it is not reasonable to believe that the test can be effective” because “it produces a higher than expected rate of false results and is higher than that in the authorized label for the device. “In the news, the company's share price fell $ 6.04, or nearly 60%, and closed at $ 3.89 per share on June 17, 2020.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

You do not need to take any action at this time to be a member of these class actions. You can keep a lawyer of your choice or take no action and remain an absent member of the class action. If you would like to learn more about these class action lawsuits, or if you have any questions about this announcement or your rights or interests in relation to these matters, please contact Frank R. Cruz of the law firms of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067, 310-914-5007, email info@frankcruzlaw.com or visit our website at www.frankcruzlaw.com. If you inquire by email, please provide your mailing address, telephone number and number of shares purchased.

In some countries, this press release may be considered a lawyer’s advertisement in accordance with applicable laws and ethical rules.

contacts

Frank R. Cruz's law firms, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here